Human dural replacement with acellular dermis: clinical results and a review of the literature.
BACKGROUND
The search for the ideal dural replacement in the setting where autogenous tissues are unavailable or inadequate still persists. Because of the ability of acellular dermis (AlloDerm, LifeCell Corporation, The Woodlands, TX) to remodel itself into native tissue, this dynamic quality is hypothesized to occur when used as a dural replacement.


METHODS
We report the long-term outcome of a small cohort of patients who, to our knowledge, were the first patients to receive AlloDerm for dural replacement. In addition, to put these current findings in a historical perspective, we present a review of the literature for dural replacement.


RESULTS
Ten patients all successfully underwent duraplasty with AlloDerm with only one postoperative complication that was not related to the acellular dermal dural repair.


CONCLUSIONS
We contend that AlloDerm is a safe and viable option for dural replacement in cases in which autogenous tissues are either unavailable or insufficient for proper reconstruction.
Costantino
P D
PD
Department of Otolaryngology-Head and Neck Surgery, The Mount Sinai Medical Center, The Mount Sinai School of Medicine, Box 1189, One Gustave L. Levy Place, New York, NY 10029, USA.
Wolpoe
M E
ME
Govindaraj
S
S
Chaplin
J M
JM
Sen
C
C
Cohen
M
M
Gnoy
A
A
D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000601:surgery*; D002102:Cadaver; D015331:Cohort Studies; D020405:Dermis / Q000637:transplantation*; D004388:Dura Mater / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D006085:Graft Survival; D006801:Humans; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D019651:Plastic Surgery Procedures / Q000379:methods; D016038:Skin Transplantation / Q000379:methods*; D016896:Treatment Outcome